AlphaQuest’s Actinium Pharmaceuticals ATNM Stock Holding History

AlphaQuest’s Portfolio ATNM Stock Details ATNM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-1	Closed	-$7	–	1877
2024 Q2	$7	Buy	+1	New	+$8	﹤0.01%	1551

Other funds holding ATNM

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

Los Angeles Capital Management Los Angeles, California $25.4B AUM 38.46% 1-Year Est. Return

Verition Fund Management Greenwich, Connecticut $15.4B AUM 30.69% 1-Year Est. Return

AlphaQuest's ATNM Position: Q3 2024 in Review

AlphaQuest sold out of Actinium Pharmaceuticals (ATNM) in Q3 2024, closing a stake of 1 share — an estimated $7 sold.

AlphaQuest first reported a position in ATNM in Q2 2024 and held it in 1 quarter. The position peaked at $7 in Q2 2024. 72 funds tracked by Wall St. Rank hold ATNM as of Q3 2024.

AlphaQuest reported no remaining Actinium Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
AlphaQuest sold 1 Actinium Pharmaceuticals share in Q3 2024, an estimated $7.
AlphaQuest first reported a position in Actinium Pharmaceuticals in Q2 2024 and held it in 1 quarter.
AlphaQuest's Actinium Pharmaceuticals position peaked at $7 in Q2 2024.
72 funds tracked by Wall St. Rank held Actinium Pharmaceuticals as of Q3 2024.

Based on AlphaQuest's 13F filing for Q3 2024, filed 7 Nov 2024.